Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 4:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 13,620 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Dermatologic Disorders Clear all

Conditions: Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid
Interventions: Questionnaires; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 3
States / cities: Philadelphia, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: Rocatinlimab, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 12 Years to 100 Years
Enrollment: 2,621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 136
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 103 more

Conditions: Breast Cancer
Interventions: PNB of SLN; Procedure
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 100 Years · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
Interventions: Binimetinib, Dabrafenib, Encorafenib, Laboratory Biomarker Analysis, Nivolumab, Pharmacological Study, Trametinib; Drug · Other · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Disorder of Nipple, Breast Neoplasms
Interventions: MRI; Device
Lead sponsor: Duke University; Other
Eligibility: 22 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
Interventions: Tissue Registry Study; Other
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Morphea, Scleroderma, Localized, Scleroderma
Interventions: FCX-013, veledimex; Genetic · Drug
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Asthma
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 1 Day to 4 Days
Enrollment: 203 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Acne Keloidalis Nuchae
Interventions: Targeted UV-B; Radiation
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Actinic Keratoses
Interventions: KX2-391 Ointment 1%; Drug
Lead sponsor: Athenex, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Actinic Keratoses
Interventions: Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C); Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Cleveland, Ohio

Conditions: Hives
Interventions: 2% Doxycycline Cream in Generic Aquaphor or Generic Aquaphor; Drug
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst, Family History of Pancreas Cancer, Genetic Mutations
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 1,368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 2
States / cities: New York, New York

Conditions: Breast Carcinoma
Interventions: Non-Interventional Study; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Breast Cancer
Interventions: Social Contact Reminder; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years and older · Female only
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Breast Cancer
Interventions: marimastat; Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 25
States / cities: Scottsdale, Arizona • Chicago, Illinois • Urbana, Illinois + 22 more

Conditions: Psoriasis
Interventions: Levia Narrow Band UVB, Levia sham/visible-light source; Device
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: DNA Repair Disorder, Cockayne Syndrome, Xeroderma Pigmentosum, Trichothiodystrophy
Interventions: Interval History, Physical Examination, ECAB Assessment, Gait Assessment, Specimen Sample Collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 40 participants
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: ptDNA, Tissue sample; Other
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: capecitabine, adjuvant therapy, radiation therapy; Drug · Procedure · Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 120 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Raynaud's Phenomenon
Interventions: placebo cream, Glyceryl Trinitrate; Drug
Lead sponsor: Procris Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Cancer
Interventions: cytomegalovirus IE-1-specific cytotoxic T lymphocytes, cytomegalovirus pp65-specific cytotoxic T lymphocytes, therapeutic allogeneic lymphocytes, polymerase chain reaction, flow cytometry, immunological diagnostic method, laboratory biomarker analysis; Biological · Genetic · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Acne Vulgaris
Interventions: SB204 2%, SB204 4%, Vehicle Gel; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 20
States / cities: Hot Springs, Arkansas • Encinitas, California • San Diego, California + 15 more

Conditions: Dermatomyositis
Interventions: Ravulizumab, Placebo; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 20
States / cities: Phoenix, Arizona • Irvine, California • Santa Monica, California + 17 more

Search by objective public record fields.

Autoimmune Blistering Diseases Study

A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)

Evaluation of Needle Core Biopsy of Axillary Sentinel Lymph Node in Breast Cancer

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Diagnostic Utility of MRI in Female Patients With Nipple Discharge: A Prospective Trial

SCRI Tissue Testing Registry

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

Use of a Probiotic Supplement to Prevent Asthma in Infants

Treatment of Acne Keloidalis Nuchae (Razor Bumps Behind the Neck) Using UV Light Therapy

Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

5-Fluorouracil and Calcipotriene for Field Treatment of Actinic Keratoses

Assessment of Suppression of Cutaneous Allergic Responses and Pruritus by Topical Doxycycline

Pancreas Registry and High Risk Registry

Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy

Utilizing Social Contacts to Facilitate Mammogram Screening Among African American Women

Marimastat or No Further Therapy in Treating Women With Metastatic Breast Cancer That Is Responding or Stable Following Chemotherapy

Use of Localized NB-UVB (Levia®) in the Treatment of Plaque-psoriasis

Natural History Study for DNA Repair Disorders

Monitoring Plasma Tumor DNA in Early-Stage Breast Cancer

Capecitabine and Radiation Therapy in Treating Patients With Nonmetastatic Breast Cancer After Surgery

Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's Phenomenon

Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections

P2 Multi-center Study of SB204 Gel in the Treatment of Acne Vulgaris

Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis